Literature DB >> 18502332

Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.

John E Paes1, Matthew D Ringel.   

Abstract

The phosphatidylinositol 3-kinase (PI3K) signaling pathway is an important regulator of many cellular events, including apoptosis, proliferation, and motility. Enhanced activation of this pathway can occur through several mechanisms, such as inactivation of its negative regulator, phosphatase and tensin homolog deleted on chromosome ten (PTEN), and activating mutations and gene amplification of the gene encoding the catalytic subunit of PI3K (PIK3CA). These genetic abnormalities have been particularly associated with follicular thyroid neoplasia and anaplastic thyroid cancer, suggesting an important role for PI3K signaling in these disorders. In this article, the role of PI3K pathway activation in thyroid cancer is discussed, with a focus on recent advances.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502332      PMCID: PMC2446602          DOI: 10.1016/j.ecl.2008.01.001

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  72 in total

1.  2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.

Authors:  Leonardo M Porchia; Marcy Guerra; Yu-Chieh Wang; Yunlong Zhang; Allan V Espinosa; Motoo Shinohara; Samuel K Kulp; Lawrence S Kirschner; Motoyasu Saji; Ching-Shih Chen; Matthew D Ringel
Journal:  Mol Pharmacol       Date:  2007-08-02       Impact factor: 4.436

Review 2.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

3.  Cancer-specific mutations in PIK3CA are oncogenic in vivo.

Authors:  Andreas G Bader; Sohye Kang; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

4.  Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.

Authors:  Adebowale J Adeniran; Zhaowen Zhu; Manoj Gandhi; David L Steward; James P Fidler; Thomas J Giordano; Paul W Biddinger; Yuri E Nikiforov
Journal:  Am J Surg Pathol       Date:  2006-02       Impact factor: 6.394

5.  Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases.

Authors:  Hye Sook Jung; Dong Wook Kim; Young Suk Jo; Hyo Kyun Chung; Jung Hun Song; Jong Sun Park; Ki Cheol Park; Su Hyeon Park; Jung Hwan Hwang; Ki-Won Jo; Minho Shong
Journal:  Mol Endocrinol       Date:  2005-06-30

6.  Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.

Authors:  Thomas J Giordano; Rork Kuick; Dafydd G Thomas; David E Misek; Michelle Vinco; Donita Sanders; Zhaowen Zhu; Raffaele Ciampi; Michael Roh; Kerby Shedden; Paul Gauger; Gerard Doherty; Norman W Thompson; Samir Hanash; Ronald J Koenig; Yuri E Nikiforov
Journal:  Oncogene       Date:  2005-10-06       Impact factor: 9.867

7.  BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.

Authors:  Norisato Mitsutake; Makoto Miyagishi; Shin Mitsutake; Nagako Akeno; Cleo Mesa; Jeffrey A Knauf; Lei Zhang; Kazunari Taira; James A Fagin
Journal:  Endocrinology       Date:  2005-10-27       Impact factor: 4.736

8.  Mutation of the PIK3CA gene in anaplastic thyroid cancer.

Authors:  Ginesa García-Rostán; Angela M Costa; Isabel Pereira-Castro; Giuliana Salvatore; Radhames Hernandez; Mario J A Hermsem; Agustin Herrero; Alfredo Fusco; Jose Cameselle-Teijeiro; Massimo Santoro
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

9.  Liphagal, a Selective inhibitor of PI3 kinase alpha isolated from the sponge akacoralliphaga: structure elucidation and biomimetic synthesis.

Authors:  Frederic Marion; David E Williams; Brian O Patrick; Irwin Hollander; Robert Mallon; Steven C Kim; Deborah M Roll; Larry Feldberg; Rob Van Soest; Raymond J Andersen
Journal:  Org Lett       Date:  2006-01-19       Impact factor: 6.005

10.  Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.

Authors:  Fumihiko Furuya; Changxue Lu; Mark C Willingham; Sheue-Yann Cheng
Journal:  Carcinogenesis       Date:  2007-07-28       Impact factor: 4.944

View more
  41 in total

1.  Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.

Authors:  Melissa E Dobson; Ericka Diallo-Krou; Vladimir Grachtchouk; Jingcheng Yu; Lesley A Colby; John E Wilkinson; Thomas J Giordano; Ronald J Koenig
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

2.  The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

Authors:  Ruixin Liu; Dingxie Liu; Eliana Trink; Ermal Bojdani; Guang Ning; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

Review 3.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

Review 4.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

5.  Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit.

Authors:  Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2009-12       Impact factor: 5.958

6.  BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.

Authors:  Dingxie Liu; Joanna Xing; Barry Trink; Mingzhao Xing
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

7.  Current concepts and future directions in differentiated thyroid cancer.

Authors:  Donald S A McLeod
Journal:  Clin Biochem Rev       Date:  2010-02

8.  Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.

Authors:  Vahid Haghpanah; Parviz Fallah; Rezvan Tavakoli; Mahmood Naderi; Hilda Samimi; Masoud Soleimani; Bagher Larijani
Journal:  Tumour Biol       Date:  2015-08-20

Review 9.  The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.

Authors:  Norman L Eberhardt; Stefan K G Grebe; Bryan McIver; Honey V Reddi
Journal:  Mol Cell Endocrinol       Date:  2009-10-31       Impact factor: 4.102

10.  Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas.

Authors:  N Burrows; J Resch; R L Cowen; R von Wasielewski; C Hoang-Vu; C M West; K J Williams; G Brabant
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.